全文获取类型
收费全文 | 910篇 |
免费 | 48篇 |
专业分类
耳鼻咽喉 | 1篇 |
妇产科学 | 2篇 |
基础医学 | 461篇 |
临床医学 | 31篇 |
内科学 | 378篇 |
皮肤病学 | 6篇 |
神经病学 | 16篇 |
特种医学 | 4篇 |
外科学 | 16篇 |
综合类 | 2篇 |
预防医学 | 6篇 |
眼科学 | 2篇 |
药学 | 12篇 |
肿瘤学 | 21篇 |
出版年
2022年 | 8篇 |
2021年 | 7篇 |
2020年 | 2篇 |
2019年 | 8篇 |
2018年 | 21篇 |
2017年 | 12篇 |
2016年 | 2篇 |
2015年 | 8篇 |
2014年 | 7篇 |
2013年 | 34篇 |
2012年 | 45篇 |
2011年 | 38篇 |
2010年 | 25篇 |
2009年 | 22篇 |
2008年 | 39篇 |
2007年 | 59篇 |
2006年 | 52篇 |
2005年 | 67篇 |
2004年 | 43篇 |
2003年 | 50篇 |
2002年 | 41篇 |
2001年 | 33篇 |
2000年 | 46篇 |
1999年 | 41篇 |
1998年 | 22篇 |
1997年 | 12篇 |
1996年 | 10篇 |
1995年 | 10篇 |
1994年 | 11篇 |
1993年 | 5篇 |
1992年 | 19篇 |
1991年 | 23篇 |
1990年 | 15篇 |
1989年 | 25篇 |
1988年 | 21篇 |
1987年 | 20篇 |
1986年 | 10篇 |
1985年 | 5篇 |
1984年 | 7篇 |
1983年 | 5篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1980年 | 6篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 1篇 |
1976年 | 2篇 |
1975年 | 1篇 |
1974年 | 1篇 |
排序方式: 共有958条查询结果,搜索用时 15 毫秒
1.
Benign hereditary leukopenia-neutropenia has been reported in several ethnic groups, including Yemenite Jews, Blacks of South African extraction, West Indians and Arab Jordanians. The subjects with BFL were shown not to have an increased incidence of infections, and their response to infection did not differ from subjects having normal white blood cell counts. This study entails the report of two additional unrelated ethnic groups with familial neutropenia - Black Beduin and Falashah Jews. The familial nature of the phenomenon was confirmed. The suggested mechanism of this type of neutropenia is a defect in release of mature WBC from the bone marrow to the peripheral circulation. All ethnic groups thus far reported have tanned or dark skin. The significance of this common feature has still to be elucidated. 相似文献
2.
Early onset of autoimmunity in MRL/++ mice following immunization with beta 2 glycoprotein I.
下载免费PDF全文
![点击此处可从《Clinical and experimental immunology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
A L Aron M L Cuellar R L Brey S Mckeown L R Espinoza Y Shoenfeld A E Gharavi 《Clinical and experimental immunology》1995,101(1):78-81
Antiphospholipid antibodies (aPL) are associated with thrombosis, thrombocytopenia and recurrent fetal loss in humans and in some animal models. Immunization with beta 2 glycoprotein I (beta 2GPI) induced aPL production in normal rabbits and mice. However, the association of these antibodies with disease manifestations remains controversial. To determine whether induction of aPL by beta 2GPI immunization in an autoimmune strain of mice (MRL/++) would result in acceleration of clinical and serological autoimmune disease manifestations, three groups of 8-week-old female mice were studied. One group was immunized with beta 2GPI, and one with ovalbumin (OVA); the third was not immunized. After two booster injections, sera were analysed for the presence of anticardiolipin (aCL) and anti-DNA by ELISA and anti-nuclear antibody (ANA) by immunofluorescence. Mice were studied for thrombocytopenia, proteinuria, fecundity rates, litter sizes and the development of central nervous system dysfunction. Elevated levels of aCL, anti-DNA and ANA were detected in all beta 2GPI-immunized, in three OVA-immunized, and in none of the unimmunized mice. The anti-DNA antibodies were inhibited by CL micelles, suggesting cross-reactivity between aCL and anti-DNA. Platelet counts, fecundity rates and litter size were reduced in beta 2GPI-immunized but not in OVA-immunized or unimmunized mice. None of the mice developed neurological dysfunction or significant proteinuria over a 10-week period post-immunization. These findings suggest that beta 2GPI immunization induces aPL in MRL/++ mice associated with accelerated autoimmune manifestations resembling the antiphospholipid syndrome. 相似文献
3.
Wu R Shoenfeld Y Sherer Y Patnaik M Matsuura E Gilburd B Koike T Peter JB 《Autoimmunity》2003,36(2):91-97
OBJECTIVE: The aim of this study was to examine whether intravenous immunoglobulin (IVIg) preparations contain anti-oxLDL and anti-anti-oxLDL antibodies. BACKGROUND: Oxidized low-density lipoprotein (oxLDL) is one of the major players in atherogenesis. IVIg can reduce atherosclerosis in experimental animal models. METHODS: Six commercial IVIg preparations were tested for the presence of anti-oxLDL antibodies by EIA. Inhibition studies were performed with the different IVIg preparations and IgGs purified from a pool of sera from patients with high anti-oxLDL antibody levels. Absorption assays were carried out to evaluate the presence of anti-idiotypes against anti-oxLDL antibodies in IVIg preparations. RESULTS: IVIg preparations tested had various degrees of reactivity towards oxLDL. Absorption experiments suggested that the reactivity was specific because it could be effectively absorbed by oxLDL and not by an irrelevant antigen PPD. The reactivity was smaller than that observed with the IgG from the pool with high anti-oxLDL antibody levels. Inhibition studies with IVIg demonstrated 20-45% inhibition of anti-oxLDL binding to oxLDL, compared to 76% inhibition by the pool with high anti-oxLDL levels. To investigate the presence of anti-idiotypes against anti-oxLDL antibodies within IVIg, F(ab')2 fragments of IVIg IgG were used to absorb IgG F(ab')2 fragments from the pool of sera with high anti-oxLDL levels. The decreased binding to oxLDL of the absorbed supernatants shows that IgG F(ab')2 fragments of the IVIg preparations had high inhibitory capacities ranging from 65 to 90%. CONCLUSIONS: IVIg preparations contain both anti-oxLDL and anti-anti-oxLDL activity. This finding may explain the immunomodulating effect of IVIg in atherosclerosis. 相似文献
4.
IVIg therapy in autoimmunity and related disorders: our experience with a large cohort of patients 总被引:1,自引:0,他引:1
Intravenous immunoglobulin (IVIg) is used to treat a number of immune-deficiencies and autoimmune diseases. It has been shown that IVIg contains anti-idiotypic antibodies, which explains its immunomodulatory action.In murine models, recent investigations have demonstrated that IVIg can prevent and reduce the affliction by systemic lupus erythematosus (SLE), antiphospholipid syndrome (APS) and scleroderma. Relevant disease-specific fractions of IVIg were able to reproduce and even enhance the therapeutic effect in a murine model.IVIg treatment before tumor resection in rodents inoculated with melanoma and sarcoma cells dramatically improved the cure rate (50%) in comparison to the control group (0%).In patients affected by SLE, several clinical manifestations responded to IVIg treatment including serositis, hematological manifestations, treatment-resistant nephritis and central nervous system involvement. Similarly, in women with recurrent fetal loss due to APS, IVIg was able to diminish the abortion rate. Vasculitides such as Churg-Strauss' and Wegener's and skin fibrosis in patients affected by scleroderma improved after IVIg treatment. In agreement with in vitro investigations, prolonged survival has been noted in cancer patients treated with IVIg.We suggest that in the presence of a steroid and immunosuppressive-resistant autoimmune disease, IVIg is a rational and safe choice. 相似文献
5.
Polymorphonuclear leukocyte (PMN) populations incubated in vitro with normal human serum are save-regulated systems of spontaneous apoptosis. Light microscopy (LM), transmission (TEM), and scanning (SEM) electron microscopes were used for the evalution of PMN apoptopic alteration. Twelve-hour PMN populations were represented by optimal number of normal and different apoptotic forms. Their ultrastructural analysis showed that on this background, 3 apoptotic cell lines (code named "first," "second," and "third") were predominated. The following characteristics were featured: "first"--vacuolization of same organelles, release of their content outside, increase of general cytoplasmic density, nuclear filling with condensed chromatin, and formation of PMNs mainly into small, round, dense forms; "second"--involvement of micronuclei or nuclei in apoptosis, their displacement to the cytoplasmic membrane and separation from the cells, and cytoplasm had numerous intact granules almost until the completion of apoptosis; "third"--synchronous apoptotic process of the nuclei and cytoplasm, moderate electronic density of cytoplasm, and granular translocation to the cell surface. Secondary necrosis was completed mainly in the apoptotic process of the "second" and "third" lines. SEM surfaces confirmed the results of TEM. This research showed that neutrophil spontaneous apoptosis is a complicated process. The 3 apoptotic cell lines reflect different pathways characteristic for the studied systems under certain conditions of cultivation. 相似文献
6.
N. Zurgil R. Bakimer M. Kaplan P. Youinou Y. Shoenfeld 《Journal of clinical immunology》1991,11(5):239-245
Antimitochondrial antibodies (AMA) may be detected in 95% of patients with primary biliary cirrhosis (PBC). The target autoantigens for the AMA were recently identified as four closely related metabolic enzymes located in the mitochondria. We have purified the pyruvate dehydrogenase (PDH) enzyme from bovine heart, showing that all PBC sera reacted with a 74-kd band. PDH was utilized to establish an ELISA assay for detecting the relevant antibodies. One hundred twelve of 120 sera from patients with PBC (95%) reacted with the PDH but none of the 201 control sera, including normal subjects and a panel of sera from other patients with liver diseases, showed similar reactivity. In 77% of the PBC sera the anti-PDH antibody isotype was identified as a combination of IgG and IgM, while in 18% only IgM was detected. In 5% of the sera the isotype was confined to IgG. PBC sera specifically inhibited the PDH enzyme activity. The enzyme inhibition correlated with the anti-PDH antibody titers. Thus, PDH seems to be one of the major target epitopes for AMA observed in sera of patients with PBC. 相似文献
7.
Goldberg I Gilburd B Kravitz MS Kivity S Chaim BB Klein T Schiffenbauer Y Trubniykovr E Brenner S Shoenfeld Y 《Clinical & developmental immunology》2005,12(1):85-90
Background: There are several mechanisms to describe allergic drug
reactions yet the methods to diagnose them are limited.
Objective: To compare several conventional clinical and laboratory
methods to diagnose skin reactions to drugs
to a new method of diagnosing drug reactions by the CellScan system.
Methods: The study entailed 21 patients who were diagnosed as
suffering from drug eruptions, and 105 healthy controls with no history of drug
allergy. The drugs were classified into two groups according to suspicion of
causing drug allergy: high and low. Most of the patients were on more than
one drug, leading to 41 patient-drug interactions (assays). Histamine
releasing test (HRT), interferon (INF)-γ releasing test and CellScan
examination were performed on lymphocytes of the patients and controls.
Results: The HRT was interpreted as positive in 9 out of 18 (50%)
patients and in 13 out of 35 (37%) assays. Based on the INF-γ releasing test,
positive results were observed in 16 out of 21 (76%) patients and in 24 out of 41
(59%) assays. In the CellScan test (CST), positive results were observed in 17
out of 21 (81%) patients and in 29 out of 41 (71%) assays. The rate of identifying
the drug for eruption in the high suspicion level drugs was 9 out of 22 (41%)
assays in the HRT, 20 out of 24 (83%) assays in the INF-γ releasing test, and 21
out of 24 (87%) studies with the CellScan method. The rate of determining of
the drug that caused the eruption in the low suspicion level drugs was 4 out of
13 (31%) in the HRT, 4 out of 17 (24%) assays in the INF-γ releasing test, and 8
out of 17 (47%) analyses in the CST. When examined
in the CellScan, 99 out of 105 (94%) controls were interpreted as negative.
Conclusion: This preliminary study indicates that the CellScan seems to
be an easy and promising method for the detection of drugs responsible for
adverse skin reactions. In contrast to the HRT and to the Interferon-γ secretion
test, the CellScan method is characterized by its ability to track and monitor
the reaction of individual cells. By measuring the kinetic parameters of selected
cells before and after adding the suspected drug, we were able to identify
the culprit drug. The CellScan method had the highest sensitivity, and the
interferon-γ secretion test had the highest specificity for detection of the culprit
drug. In contrast, the analysis of 105
normal control sera disclosed a high specificity of 94% for the CellScan method. 相似文献
8.
Induction of biologically active antineutrophil cytoplasmic antibodies by immunization with human apoptotic polymorphonuclear leukocytes 总被引:4,自引:0,他引:4
Rauova L Gilburd B Zurgil N Blank M Guegas LL Brickman CM Cebecauer L Deutsch M Wiik A Shoenfeld Y 《Clinical immunology (Orlando, Fla.)》2002,103(1):69-78
Translocation of intracellular components to the cell surface during the priming or apoptosis of polymorphonuclear leukocytes (PMN) is an important mechanism for interaction of antineutrophil cytoplasmic antibodies (ANCA) with these antigens. To test the capacity of apoptotic PMN to trigger production of ANCA, six groups of mice were immunized with either live or apoptotic lymphocytes, or with live, apoptotic, formalin-fixed, or lysed PMN. Mice immunized with both live and apoptotic neutrophils developed high titers of antibodies which gave a granular cytoplasmic immunofluorescent pattern. These antibodies were specific for lactoferrin and myeloperoxidase. Following a second intravenous infusion of apoptotic PMNs, mice developed anti-PR3 antibodies. Vasculitis lesions were not found in mice which developed ANCA. The ANCA-containing IgG fraction induced superoxide production by human PMNs. These results support the hypothesis that neutrophil-specific antigens presented on the cell membranes of apoptotic PMN may induce ANCA in the proper conditions. 相似文献
9.
BACKGROUND: Stimulation and proliferation of lymphocytes require activation of Ras. S-farnesylthiosalicylic acid (FTS) is a synthetic substance that detaches Ras from the inner cell membrane and induces its rapid degradation. Antiphospholipid antibodies (aPL) are a heterogeneous group of antibodies detected in patients with antiphospholipid syndrome (APS), which is associated with thrombosis, pregnancy losses, and thrombocytopenia. OBJECTIVE: To examine the effect of FTS treatment on aPL levels in a genetic autoimmune model (the MRL/lpr mice) and in an induced model of APS. METHODS: Female Balb/C mice immunized once with beta2-glycoprotein I (beta2-GPI) in complete Freund's adjuvant (CFA) and female MRL/lpr mice were treated intraperitoneally with either FTS (5 mg/Kg/day) or saline 3-5 times a week. aPL and anti-beta2-GPI antibodies were measured by ELISA. RESULTS: FTS treatment 3 times a week resulted in significant decreases of aPL and anti-beta2-GPI antibodies in both animal models. In contrast, more frequent treatment (5 times a week) had no significant effect on autantibody levels in both animal models. We further compared 2 protocols in the induced APS model, one for alternate day treatment and the other for daily treatment on the first 3 days each week, and found a decrease in autoantibody levels only in the alternate day protocol. CONCLUSIONS: Inhibition of Ras activation by FTS is effective in decreasing autoantibody levels in models of APS. The differential modulation of immune function by alternate day compared to daily treatment may provide better understanding of the role of Ras activation in this system. 相似文献
10.
Yaron Bar-Dayan M. Eric Gershwin Yair Levi Howard Amital Dr. Yehuda Shoenfeld 《Immunologic research》1998,18(2):117-123
Primary biliary cirrhosis (PBC) is a chronic, progressive cholestatic liver disease, which is invariably fatal. Circumstantial and indirect evidence suggests that autoimmune mechanisms have a role in the pathogenesis of PBC. Antimitochondrial antibodies (AMA) are highly sensitive and specific markers that can predict the development of the disease in a healthy individual. Long-term administration of ursodeoxycholic acid (UDCA), a naturally occurring bile acid, safely slows the progression of PBC, delays the need for liver transplantation, and postpones death. An effort should be made to identify the patients with PBC in the asymptomatic stage by the presence of AMA and to conduct a clinical trial in order to assess the benefit of long-term administration of UDCA on the prevention of the overt disease in these individuals. 相似文献